TLX:ASXTelix Pharmaceuticals Limited Analysis

Technical signals show TLX trading at $13.79, just above its 20‑day SMA (13.40) but below the 50‑day SMA (14.20), indicating a neutral to mildly bullish bias. The RSI sits at 52.6, well within the 30‑70 comfort zone, while the MACD histogram is positive and the MACD line sits above its signal line, suggesting short‑term momentum is turning bullish. Volume is on an increasing trend, and the price is comfortably above the identified support at $12.17, with resistance near $15.09. However, 30‑day volatility is high at ~38% and the stock’s beta of 0.57 points to lower market‑wide correlation but heightened price swings.
Fundamental backdrop reveals a rapidly growing top line (+49% YoY revenue to $804 M) and a respectable gross margin of 47.5%, yet profitability remains elusive with a negative profit margin (-0.9%) and negative cash flows. The balance sheet is leveraged, featuring $467 M of debt versus $142 M of cash (debt‑to‑equity >112%). Forward earnings are modest ($0.11 EPS) leading to an inflated forward P/E of 120.6, far above the industry average of 24.7, and a P/B of 7.78. Analysts are optimistic, assigning a “strong_buy” consensus, a median price target of $21.45 and a 69% upside potential, while the Fear & Greed Index sits at “Extreme Greed” (92.5).